Background
==========

Sex medicine aims to investigate how diseases differ between men and women in terms of prevalence, manifestation, severity, therapeutic approach, and prognosis. Sex differences with regard to disease characteristics and/or therapeutic approach have been reported in immune-mediated inflammatory diseases, including rheumatoid arthritis, inflammatory bowel diseases, and psoriasis.[@b1-ccid-9-001],[@b2-ccid-9-001] Marked sex differences have also been described in the susceptibility to viral infections, other than their incidence and manifestations.[@b3-ccid-9-001]--[@b7-ccid-9-001] This observation may be linked to the fact that sex hormones seem to have significant effects on cell-mediated immune responses, as shown by several clinical and experimental studies.[@b8-ccid-9-001]--[@b10-ccid-9-001]

Psoriatic arthritis (PsA) is a disabling complication that occurs in 6%--39% of psoriatic patients,[@b11-ccid-9-001] usually following skin manifestations and generally characterized by synovitis, enthesitis, dactylitis, and spondylitis.[@b12-ccid-9-001] Patients with PsA are often treated with systemic immunosuppressant agents (eg, steroids, methotrexate, cyclosporin A \[CsA\]), which are known to increase the risk of new infections or of previous infection reactivation, though clinical data are scarce. Regarding anti tumor necrosis factor alpha, data suggest that therapy with these agents would appear efficacious and reasonably safe in the management of PsA patients with concomitant infections.[@b13-ccid-9-001]--[@b17-ccid-9-001]

The Observational Study of infectious events in psoriasis complicated by active psoriatic arthritis (SYNERGY) study is a cross-sectional and longitudinal (12 months) multi-center Italian study, involving 238 consecutive patients with diagnosis of PsA performed within 8 years from baseline, treated from at least 3 months with CsA as monotherapy or in combination with one or more systemic drugs. The SYNERGY study aimed at assessing: 1) seropositivity for former and acute viral infection; 2) effectiveness of CsA alone or in combination in a time period of 12 months; and 3) occurrence of infections or other adverse events during the study period.[@b18-ccid-9-001] The results revealed a high prevalence of viral seropositivity -- herpes simplex virus 1 (92.3%), herpes simplex virus 2 (67%), varicella-zoster virus (95.3%), Epstein--Barr virus (89.2%), cytomegalovirus (77.3%), and hepatitis B virus (6.1%) -- but no viral reactivation during the 12-month observation period. However, sex differences in seropositivity were not analyzed. Since many differences between sexes have been reported in psoriatic patients, in terms of epidemiology,[@b19-ccid-9-001] pattern and burden of disease,[@b20-ccid-9-001] but also in immune response as well as susceptibility to viral infections,[@b21-ccid-9-001] it was decided to perform a post hoc analysis to evaluate for potential differences between sexes in severity of disease, response to treatment, and prevalence of viral infections.

Methods
=======

Ethical approval was obtained from the Ethical Committee of "G. Pini" Institute of Milan (principal center) and then from each participating center and signed informed consent was obtained from participating patients. SYNERGY was a cross-sectional and longitudinal (12 months) observational study, conducted in 24 Italian dermatology clinics, which included 238 consecutively enrolled patients with PsA. Patients and methods of the study are described in detail elsewhere.[@b18-ccid-9-001]

Patients of the SYNERGY study were considered evaluable for this post hoc analysis, provided that sex was specified. According to the SYNERGY inclusion criteria, patients had: a diagnosis of psoriasis complicated by PsA, according to the ClASsification for Psoriatic ARthritis criteria[@b22-ccid-9-001],[@b23-ccid-9-001] performed within 8 years before baseline;an ongoing treatment with immunosuppressant regimens including CsA;no other form of arthritis besides PsA.

In this analysis, the following variables were compared between sexes at baseline and at 6 and 12 months of follow-up: age and demographical characteristics;age at diagnosis of psoriasis;duration of psoriasis;vaccinations administered;body surface area;Psoriasis Area and Severity Index (PASI);Bath Ankylosing Spondylitis Disease Activity Index (BASDAI);global activity of disease;number of painful and swollen joints;seropositivity for at least one infection;treatments for PsA (topical, infiltrations, systemic, ie, cyclosporine, methotrexate, biologics);pharmacological treatments for infections;adverse events.

The BASDAI is a useful composite measure in spondyloarthropathies and, when the SYNERGY study was designed, it was chosen hypothesizing that, since PsA has both peripheral and axial clinical manifestations, indices that measure only peripheral joint activity, such as the Disease Activity Score or the American College of Rheumatology response criteria, may not capture sufficient information to truly reflect disease activity in PsA.

Indexes of disease severity and activity were also compared between premenopausal and postmenopausal women and men of corresponding age, taking as cut off 50 years, since in Italy, the average age for last period is \~50 years.[@b24-ccid-9-001]

All analyses were performed with SAS version 9.2 (SAS Institute Inc., Cary, NC, USA) and Enterprise Guide 4.3 (SAS Institute Inc., Cary, NC, USA). Descriptive analyses were mean and standard deviation (SD), or median and inter-quartile range. Comparisons were performed by Student's *t*-test, chi-square test, or Fisher's exact test, if appropriate. The accepted level of significance was set at alpha =0.05. As post hoc analyses, all *P*-value presented are exploratory.

Results
=======

In the SYNERGY study, 238 patients were enrolled, but 13 patients not fulfilling the inclusion criteria were excluded from the analysis.[@b18-ccid-9-001] Therefore, 225 patients were evaluated in this post hoc analysis, of which 121 (54%) were males. The distribution of patients according to sex, age, and concomitant diseases at baseline is shown in [Table 1](#t1-ccid-9-001){ref-type="table"}; no statistically significant differences were observed between males and females with respect to these variables (*P*-values males vs females \>0.05) as well as in the vaccination profile (2.5% of males and 6.7% of females were vaccinated at baseline; Fisher's exact test, *P*-value =0.2045).

Regarding the severity of psoriasis, PASI score at baseline was significantly higher in males compared with females (8.0 \[SD 7.7\] in males vs 5.8 \[SD 6.9\] in females; *t*-test, *P*-value =0.028). As shown in [Figure 1](#f1-ccid-9-001){ref-type="fig"}, in terms of severity of PsA at baseline, differences between sexes emerged in the mean number of painful (but not of swollen) joints and in the global activity of disease, as assessed by patients (but not by physicians). Consistently, also the BASDAI at baseline was higher in females (44.9 \[SD 22.9\]) than in males (36.5 \[SD 22.8\]; *t*-test, *P*-value =0.036). Severity of both psoriasis and PsA progressively diminished at 6 and 12 months of follow-up, as did differences between sexes, which were no longer significant after baseline except for painful joint count at 6-month follow-up (4.6 \[SD 7.5\] in males vs 8.0 \[SD 10.1\] in females; *t*-test, *P*-value =0.0162) and swollen joint count at 12-month follow-up (0.7 \[SD 1.4\] in males vs 1.6 \[3.4\] in females; *t*-test, *P*-value =0.0358).

As regards infections, the percentage of patients with at least one seropositivity detected at baseline, indicative of former viral infection, was significantly higher among women (68.3%) than among men (53.7%; chi-square test, *P*-value =0.011). As shown by the SYNERGY study, none of these patients developed viral or other infectious diseases during the 12 month follow-up nor developed virus reactivation.

When PASI and BASDAI as indexes of activity of psoriasis and PsA, respectively, were analyzed according to pre- or postmenopausal status in women and compared with men of corresponding age (ie, \<50 years and ≥50 years), no statistically significant differences between sexes were observed at baseline and at 6 and 12 months of follow-up in either age groups ([Table 2](#t2-ccid-9-001){ref-type="table"}).

No differences were observed between males and females in terms of treatment, either in the percentage of treated patients or in the type of medications administered ([Table 3](#t3-ccid-9-001){ref-type="table"}).

Finally, adverse events during study were reported in eight men and seven women (chi-square test, *P*-value\>0.05).

Discussion
==========

Awareness of sex differences in diseases is important among professionals. In order to manage such differences, clinicians should provide for a highly specialized care, which might be particularly useful in psoriasis to provide an equal quality of care for women, who have been reported to suffer from a higher psychosocial distress and a greater impact on quality of life.[@b25-ccid-9-001],[@b26-ccid-9-001] It has also been reported that peripheral joint involvement and pain are more frequent among female psoriatic patients than among male patients.[@b27-ccid-9-001],[@b28-ccid-9-001] Another recently published article confirmed the greater peripheral involvement in women with PsA (with more frequent polyarthritis) as well as greater physical functional impairment.[@b29-ccid-9-001] In our analysis, consistently, a significantly greater number of painful joints as well as greater patients' assessed activity of PsA were observed in female compared to male patients. On the other hand, slightly higher PASI values were observed in men compared to women at baseline. All the aforementioned sex differences disappeared at follow-up visits, but this may be easily explained by the overall progressive improvement of the disease during the study, likely due to participation in the trial per se, sustained pharmacological treatment, and increased use of biologics in combination with CsA during the course of the study, as reported in the SYNERGY paper.[@b18-ccid-9-001]

Concerning the pattern of infections, interestingly a higher percentage of women had seropositivity for at least one viral infection. The explanation for this difference is not clear, but might be related to the greater humoral immune responses of females to viral antigens, reported by many authors.[@b30-ccid-9-001]--[@b33-ccid-9-001] The reason for these differences in susceptibility to infections between males and females has been reported to be multifactorial. The primary cause is thought to be due to differences induced by sex hormones and their effects on gene expression as well as the immune system, but may also be due to innate physiological differences between males and females. It has also been suggested that there may be an interaction between sex-specific immune differences and the specific immune response to individual microbes. Menopausal status seems not to affect the severity of disease among women, since stratifying the study population by age (\<50 years or ≥50 years) seems to flatten differences between sexes. This might be due to the lower sample size in each group.

An important aspect, already pointed out by the SYNERGY study, is that treatment with CsA alone or combined with other immunosuppressant seems not to favor the reactivation of severe viral infections in previously infected patients, with no difference between females and males, even though men have been reported to have an underlying immunosuppressed condition compared to women, due to the immunosuppressive effects of male steroidal sex hormones.[@b34-ccid-9-001]--[@b36-ccid-9-001]

Finally, the observation of no difference in the therapeutic approach between sexes is consistent with the findings of the previously conducted MetaGeM analysis of the PSYCHAE study,[@b37-ccid-9-001] confirming that Italian physicians do not adopt different approaches between sexes, even though articular involvement, activity of disease, and psychological distress have been reported to be worse in females.

We are aware that this paper has a limitation to be a post hoc analysis of a study, not specifically aimed at assessing sex differences. Thus, the sample size was not calculated on this specific hypothesis and furthermore, data collection may have missed relevant information. Due to the relatively small sample size, we could not further split the male--female patient populations by CsA monotherapy or combination therapy, and this may be considered another limitation, since the potential interactions with concomitant medications have not been addressed. On the other hand, because of the exploratory aim of these analyses, the significance threshold was set to 0.05 and not corrected.[@b38-ccid-9-001]

Conclusion
==========

The present post hoc sex analysis of the SYNERGY study shows a greater articular involvement and a higher self-assessed disease activity in female patients with PsA as compared to males, which, together with the heavier psychological distress reported in the PSYCHAE study, further suggest that psoriatic women may deserve more attention and probably a slightly different therapeutic approach, including psychological support. Moreover, our analysis shows a higher percentage of viral seropositivities among women. Finally, cyclosporine treatment seems not to induce hepatitis B virus or hepatitis C virus reactivation in either sex.
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###### 

Age, concomitant diseases, and viral status of the SYNERGY male and female patients at baseline

                                 Males (N=121)   Females (N=104)   *P*-value
  ------------------------------ --------------- ----------------- -----------
  Age, mean (SD)                 48.9 (12.8)     50.8 (12.5)       0.2499
  **Concomitant diseases (%)**   45.5            48.1              0.6942
  Cardiovascular diseases        24.8            30.8              
  Type 1 diabetes                3.3             0                 
  Type 2 diabetes                7.4             3.8               
  Cerebrovascular diseases       0               1                 
  Renal diseases                 2.5             1.9               
  Other diseases                 21.5            21.2              
  *Viral positivity (%)*         53.7            68.3              0.0105
  HBV                            5               3.8               
  HCV                            5.8             3.8               
  Cytomegalovirus                36.4            46.2              
  HIV 1--2                       0               0                 
  HSV 1                          42.1            53.8              
  HSV 2                          31.4            37.5              
  Varicella-zoster virus         17.4            19.2              
  Epstein--Barr virus            32.2            42.3              

**Abbreviations:** HBV, hepatitis B virus; HCV, hepatitis C virus; HIV, human immunodeficiency virus; HSV, herpes simplex virus; SD, standard deviation; SYNERGY, Observational Study of infectious events in psoriasis complicated by active psoriatic arthritis.

###### 

PASI and BASDAI in pre- and postmenopausal women compared to age-matched men at each study time point

  --------------------------------------------------------------------------------------------------------------------
                         PASI mean (SD)   BASDAI mean (SD)                                              
  ---------------------- ---------------- ------------------ ------------ -------------- -------------- --------------
                                                                                                        

  Premenopausal women    5.9 (7.2)\       3.0 (4.4)\         2.3 (4.0)\   36.6 (22.3)\   28.5 (25.0)\   26.2 (29.9)\
                         **N=64**         **N=48**           **N=50**     **N=40**       **N=23**       **N=19**

                                                                                                        

  Men aged \<50 years\   8.2 (7.7)\       4.9 (6.9)\         4.1 (6.4)\   31.6 (22.8)\   28.6 (27.3)\   23.9 (23.6)\
  *P*-value              0.1047\          0.1383\            0.1147\      0.3994\        0.9944\        0.7992\
                         **N=53**         **N=46**           **N=42**     **N=36**       **N=26**       **N=21**

                                                                                                        

  Postmenopausal women   5.7 (6.6)\       3.1 (5.1)\         2.9 (4.7)\   50.3 (21.9)\   38.1 (23.3)\   28.5 (24.1)\
                         **N=56**         **N=45**           **N=45**     **N=34**       **N=22**       **N=16**

                                                                                                        

  Men aged ≥50 years\    7.7 (7.8)\       3.6 (3.8)\         2.8 (4.1)\   42.2 (21.7)\   30.0 (26.1)\   21.0 (15.6)\
  *P*-value              0.1487           0.5467             0.9591       0.1279         0.2629         0.2825
  --------------------------------------------------------------------------------------------------------------------

**Abbreviations:** BASDAI, Bath Ankylosing Spondylitis Disease Activity Index; PASI, Psoriasis Area Severity Index; SD, standard deviation.

###### 

Systemic pharmacological treatment for psoriasis and psoriatic arthritis

  Type of systemic treatment    Baseline[\*](#tfn3-ccid-9-001){ref-type="table-fn"}   Follow-up[\*\*](#tfn4-ccid-9-001){ref-type="table-fn"}               
  ----------------------------- ----------------------------------------------------- -------------------------------------------------------- ----------- -----------
  Cyclosporine                  58 (47.9)                                             52 (50.0)                                                52 (43.0)   42 (40.4)
  Cyclosporine + methotrexate   17 (14.0)                                             19 (18.3)                                                19 (15.7)   15 (14.4)
  Cyclosporine + biologics      16 (13.2)                                             7 (6.7)                                                  24 (19.8)   21 (20.2)
  Cyclosporine + other          24 (19.8)                                             21 (20.2)                                                16 (13.2)   17 (16.3)
  Other, not specified          6 (5.0)                                               5 (4.8)                                                  10 (8.3)    9 (8.7)

**Notes:**

At baseline, treatment assumed during the last 12 months were recorded;

follow-up refers to the 12th month of study observation period. Other drugs include NSAIDs, corticosteroids, sulfasalazine, retinoids, etc.

**Abbreviation:** NSAIDS, non-steroidal anti-inflammatory drugs.
